EGFR blockade prevents glioma escape from BRAFV600E targeted therapy

EGFR blockade prevents glioma escape from BRAFV600E targeted therapy

Mutational activation of BRAF (BRAFV600E) occurs in pediatric glioma and drives aberrant MAPK signaling independently of upstream cues. Targeted monotherapy against BRAFV600E displays efficacy in pre-clinical models of glioma, however xenograft tumors adapt rapidly and escape from the growth-inhibit...

Full description

Bibliographic Details
Main Authors:	Yao, Tsun-Wen, Zhang, Jie, Prados, Michael, Weiss, William A., James, C. David, Nicolaides, Theodore
Format:	Online
Language:	English
Published:	Impact Journals LLC 2015
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4673141/

Similar Items

BRAFV600E protein expression and outcome from BRAF inhibitor treatment in BRAFV600E metastatic melanoma
by: Wilmott, J S, et al.
Published: (2013)

Biological insights into BRAFV600 mutations in melanoma patient: Not mere therapeutic targets
by: Improta, Giuseppina, et al.
Published: (2013)

Intra- and Inter-Tumor Heterogeneity of BRAFV600EMutations in Primary and Metastatic Melanoma
by: Yancovitz, Molly, et al.
Published: (2012)

The BRAFV600E mutation: what is it really orchestrating in thyroid cancer?
by: Nucera, Carmelo, et al.
Published: (2010)

BRAFV600E Negatively Regulates the AKT Pathway in Melanoma Cell Lines
by: Chen, Brenden, et al.
Published: (2012)

Clinical implication of the BRAFV600E mutation in papillary thyroid carcinoma
by: Kim, Yong-Seok, et al.
Published: (2013)

Vemurafenib enhances MHC induction in BRAFV600E homozygous melanoma cells
by: Sapkota, Bishu, et al.
Published: (2013)

Multifocal BRAFV600E-Mutated Melanoma in situ on the Foot
by: Iwama, Eimei, et al.
Published: (2015)

Response of recurrent BRAFV600E mutated ganglioglioma to Vemurafenib as single agent
by: del Bufalo, Francesca, et al.
Published: (2014)

Lack of BRAFV600E mutation in stage I and II of colorectal cancer
by: Molaei, Mahsa, et al.
Published: (2016)

Targeted Therapies Compared to Dacarbazine for Treatment of BRAFV600E Metastatic Melanoma: A Cost-Effectiveness Analysis
by: Shih, Vanessa, et al.
Published: (2015)

A Genetic Progression Model of BrafV600E-Induced Intestinal Tumorigenesis Reveals Targets for Therapeutic Intervention
by: Rad, Roland, et al.
Published: (2013)

Clinicopathological features and BRAFV600E mutations in patients with isolated hypothalamic-pituitary Langerhans cell histiocytosis
by: Huo, Zhen, et al.
Published: (2016)

Activation of the Mitochondrial Fragmentation Protein DRP1 Correlates with BRAFV600E Melanoma
by: Wieder, Shira Y., et al.
Published: (2015)

Value of TIRADS, BSRTC and FNA-BRAFV600E mutation analysis in differentiating high-risk thyroid nodules
by: Zhang, Yu-zhi, et al.
Published: (2015)

Targeted Therapy for MAPK Alterations in Pediatric Gliomas
by: Truong, AY, et al.
Published: (2015)

Beyond BRAFV600: clinical mutation panel testing by next-generation sequencing in advanced melanoma
by: Siroy, Alan E., et al.
Published: (2014)

Effect of BRAFV600E mutation on transcription and post-transcriptional regulation in a papillary thyroid carcinoma model
by: Cahill, Susanne, et al.
Published: (2007)

Selective BRAFV600E Inhibitor PLX4720, Requires TRAIL Assistance to Overcome Oncogenic PIK3CA Resistance
by: Oikonomou, Eftychia, et al.
Published: (2011)

Is Follow-up BRAFV600E Mutation Analysis Helpful in the Differential Diagnosis of Thyroid Nodules with Negative Results on Initial Analysis?
by: Yoon, Jung Hyun, et al.
Published: (2013)

Diagnostic utility of BRAFV600E mutation testing in thyroid nodules in elderly patients
by: Guerra, Anna, et al.
Published: (2013)

The relationship between the BRAFV600E mutation in papillary thyroid microcarcinoma and clinicopathologic factors
by: Choi, Sun Yi, et al.
Published: (2013)

Automated Universal BRAF State Detection within the Activation Segment in Skin Metastases by Pyrosequencing-Based Assay U-BRAFV600
by: Skorokhod, Alexander, et al.
Published: (2013)

BRAFV600E Mutation and Its Association with Clinicopathological Features of Colorectal Cancer: A Systematic Review and Meta-Analysis
by: Chen, Dong, et al.
Published: (2014)

BRAFV600E immunohistochemistry in conjunction with mismatch repair status predicts survival in patients with colorectal cancer
by: Toon, Christopher W, et al.
Published: (2014)

Genetic inactivation or pharmacological inhibition of Pdk1 delays development and inhibits metastasis of BrafV600E::Pten−/− melanoma
by: Scortegagna, Marzia, et al.
Published: (2013)

Analysis of BRAFV600E mutation and DNA methylation improves the diagnostics of thyroid fine needle aspiration biopsies
by: Zhang, Bingfei, et al.
Published: (2014)

Lkb1 Loss Promotes Tumor Progression of BRAFV600E-Induced Lung Adenomas
by: González-Sánchez, Elena, et al.
Published: (2013)

Proper Indication of BRAFV600E Mutation Testing in Fine-Needle Aspirates of Thyroid Nodules
by: Koh, Jieun, et al.
Published: (2013)

Effect of dabrafenib on melanoma cell lines harbouring the BRAFV600D/R mutations
by: Gentilcore, Giusy, et al.
Published: (2013)

Impact of MAPK Pathway Activation in BRAFV600 Melanoma on T Cell and Dendritic Cell Function
by: Ott, Patrick A., et al.
Published: (2013)

S100A4 Knockout Sensitizes Anaplastic Thyroid Carcinoma Cells Harboring BRAFV600E/Mt to Vemurafenib
by: Xuelong Jiao, et al.
Published: (2018-09-01)

SIRT6 haploinsufficiency induces BRAFV600E melanoma cell resistance to MAPK inhibitors via IGF signalling
by: Thomas Strub, et al.
Published: (2018-08-01)

Sema6A and Mical1 control cell growth and survival of BRAFV600E human melanoma cells
by: Loria, Rossella, et al.
Published: (2014)

NRASQ61R, BRAFV600E immunohistochemistry: a concomitant tool for mutation screening in melanomas
by: Uguen, Arnaud, et al.
Published: (2015)

The BRAFV600E inhibitor, PLX4032, increases type I collagen synthesis in melanoma cells
by: Jenkins, Molly H., et al.
Published: (2015)

Associations between BRAFV600E and prognostic factors and poor outcomes in papillary thyroid carcinoma: a meta-analysis
by: Liu, Chunping, et al.
Published: (2016)

Diagnostic value of BRAFV600E-mutation analysis in fine-needle aspiration of thyroid nodules: a meta-analysis
by: Su, Xingyun, et al.
Published: (2016)

Pluripotency markers are differentially induced by MEK inhibition in thyroid and melanoma BRAFV600E cell lines
by: Dorris, Emma R., et al.
Published: (2016)

Clinicopathological Features and Prognosis of Papillary Thyroid Microcarcinoma for Surgery and Relationships with the BRAFV600E Mutational Status and Expression of Angiogenic Factors
by: Shi, Chenlei, et al.
Published: (2016)